查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1708012

全球液态切片市场：行业分析、规模、份额、成长、趋势和预测（2025-2032）

Lung Cancer Liquid Biopsy Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2025 - 2032
出版日期: | 出版商: Persistence Market Research | 英文 180 Pages | 商品交期: 2-5个工作天内

价格
简介目录

主要发现

  • 肺癌液态切片市场规模：8.247亿美元（2025年）
  • 预计市场价值：19.5亿美元（2032年）
  • 全球市场成长率：12.7%（2025年至2032年的复合年增长率）

肺癌液态切片市场 - 报告范围

肺癌液态切片市场专注于利用血液和其他体液检测肺癌患者的肿瘤生物标记的非侵入性诊断方法。这些切片检查正在彻底改变癌症的诊断和管理，具有快速的周转时间、减少患者的不适以及即时监测肿瘤进展和治疗反应等特征。随着全球肺癌发生率的上升和精准医疗的普及，液态切片正成为肿瘤诊断的强大工具。该市场涵盖广泛的产品和服务，包括专为小细胞肺癌（SCLC）和非小细胞肺癌（NSCLC）的早期检测、基因分析和治疗指导而设计的仪器、试剂和生物资讯解决方案。

市场成长动力

全球肺癌液态切片市场的成长主要受到全球肺癌盛行率上升和微创诊断方法需求增加的推动。分子诊断技术的进步，特别是次世代定序（NGS）和基于PCR的技术，使得液态切片测试更加准确和容易获得。此外，对个人化医疗的日益关注鼓励医疗保健提供者和肿瘤学家采用液态切片进行即时肿瘤分析和监测。支持性监管核准和不断增加的医疗保健支出（尤其是在已开发国家）进一步促进了市场的扩张。人们对早期和准确的癌症检测方法的日益增长的偏好以及液态切片在克服传统组织切片检查局限性方面的潜力也在推动市场需求。

市场限制

儘管成长轨迹看好，液态切片市场仍面临几个挑战。先进液态切片技术的高成本可能会限制其应用，尤其是在中低收入国家。一些检测的敏感性和特异性仍然令人担忧，特别是在早期癌症检测中，因为它们可能会产生假阳性或假阴性。一些地区患者和医疗保健提供者的认知度较低也阻碍了市场渗透。此外，严格的法规结构和报销障碍可能会延迟产品发布或限制获取，从而影响整体市场的成长。

市场机会

由于对细胞外囊泡和循环性肿瘤细胞等新型生物标记的研究不断扩大，可以提高诊断的准确性，因此液态切片市场提供了重大机会。多分析液态切片面板的持续发展以及人工智慧和机器学习在生物资讯学中的整合为提高诊断准确性和效率提供了途径。新兴经济体，尤其是亚太和拉丁美洲的新兴经济体，由于癌症发病率的上升和医疗保健基础设施的扩大，拥有尚未开发的潜力。此外，诊断公司和製药公司在标靶治疗的伴同性诊断方面的合作正在开闢新的成长途径。持续投资于旨在检验新的生物标记组合的研发和临床试验将推动创新和市场竞争力。

本报告研究了全球液态切片市场，并对市场动态进行了详细分析，包括成长动力、趋势、机会和挑战。

目录

第一章执行摘要

第二章 市场概述

  • 市场范围和定义
  • 市场动态
    • 驱动程式
    • 限制因素
    • 机会
    • 主要趋势
  • 宏观经济因素
    • 全球产业展望
    • 全球GDP成长前景
  • COVID-19影响分析
  • 预测因子－相关性和影响力

第三章 增值考虑

  • 产品采用分析
  • 疾病流行病学
  • 监管格局
  • 供应商名单
  • 波特五力分析
  • PESTLE分析
  • 主要企业促销策略

第四章 全球肺癌液态切片展望

  • 主要亮点
    • 市场规模及与前一年同期比较
    • 绝对的商机
  • 市场规模分析与预测
    • 市场规模表现分析（2019-2024）
    • 当前市场规模分析与预测（2025-2032）
  • 全球肺癌液态切片展望：产品
    • 简介/主要发现
    • 市场规模绩效分析：依产品（2019-2024 年）
    • 目前市场规模分析及产品预测（2025-2032）
      • 装置
      • 套件和试剂
      • 软体、服务
    • 市场吸引力分析：产品
  • 全球肺癌液态切片展望：技术
    • 简介/主要发现
    • 依技术分類的市场规模表现（2019-2024 年）
    • 目前市场规模分析及技术预测（2025-2032）
      • 多基因平行分析（NGS）
      • 单基因分析（PCR微阵列）
    • 市场吸引力分析：技术
  • 全球液态切片展望：生物标誌物
    • 简介/主要发现
    • 生物标记市场规模表现（2019-2024）
    • 生物标记目前市场规模分析及预测（2025-2032）
      • cfDNA
      • ctDNA
      • 细胞外囊泡（EVs）
      • 循环性肿瘤细胞（CTC）
      • 其他的
    • 市场吸引力分析：生物标记
  • 全球肺癌液态切片展望：适应症
    • 简介/主要发现
    • 市场规模表现（依适应症划分） (2019-2024)
    • 目前市场规模分析及预测（2025-2032）
      • 小细胞肺癌（SCLC）
      • 非小细胞肺癌（NSCLC）
    • 市场吸引力分析：迹象
  • 全球液态切片展望：样本
    • 简介/主要发现
    • 市场规模表现（依样本）（2019-2024 年）
    • 目前市场规模分析及样本预测（2025-2032）
      • 血
      • 脑脊髓液（CSF）
      • 电浆
      • 血清
      • 其他的
    • 市场吸引力分析：范例
  • 全球肺癌液态切片展望：最终用户
    • 简介/主要发现
    • 最终用户的市场规模表现（2019-2024）
    • 目前市场规模分析及最终用户预测（2025-2032）
      • 医院
      • 参考实验室
      • 学术研究所
      • 其他的
    • 市场吸引力分析：最终用户

5. 全球肺癌液态切片地区展望

  • 主要亮点
  • 市场规模绩效分析：按地区（2019-2024）
  • 目前市场规模分析及各地区预测（2025-2032）
    • 北美洲
    • 欧洲
    • 东亚
    • 南亚和大洋洲
    • 拉丁美洲
    • 中东和非洲
  • 市场吸引力分析：地区

6. 北美肺癌液态切片展望

7. 欧洲肺癌液态切片展望

第八章 东亚肺癌液态切片展望

9. 南亚和大洋洲肺癌液态切片展望

10. 拉丁美洲肺癌液态切片前景

11. 中东和非洲肺癌液态切片展望

第十二章竞争格局

  • 市场占有率分析（2025年）
  • 市场结构
    • 竞争强度图：按市场
    • 竞争仪錶板
  • 公司简介（详情－概述、财务状况、策略、最新发展）
    • Bio-Rad Laboratories, Inc.
    • Agilent Technologies, Inc.
    • Oncocyte Corporation
    • NeoGenomics Laboratories
    • Lepu Medical Technology (Beijing) Co., Ltd
    • QIAGEN
    • Thermo Fisher Scientific Inc.
    • Illumina, Inc.
    • F. Hoffmann-La Roche Ltd
    • Sysmex Corporation
    • BioView
    • Guardant Health, Inc
    • SOPHiA GENETICS
    • BioMark Diagnostics
    • DELFI Diagnostics, Inc.
    • Freenome Holdings, Inc.
    • Foresight Diagnostics, Inc.
    • Foundation Medicine, Inc.
    • Pillar Biosciences, Inc.
    • Caris Life Sciences

第十三章 附录

简介目录
Product Code: PMRREP35195

Persistence Market Research has recently released a comprehensive report on the global Lung Cancer Liquid Biopsy Market, providing an in-depth analysis of key market dynamics, including driving forces, emerging trends, opportunities, and challenges. This report offers a detailed understanding of the market landscape, helping stakeholders make well-informed decisions.

Key Insights:

  • Lung Cancer Liquid Biopsy Market Size (2025E): US$ 824.7 Mn
  • Projected Market Value (2032F): US$ 1,900.5 Mn
  • Global Market Growth Rate (CAGR 2025 to 2032): 12.7%

Lung Cancer Liquid Biopsy Market - Report Scope:

The lung cancer liquid biopsy market focuses on non-invasive diagnostic methods that utilize blood and other body fluids to detect tumor biomarkers in lung cancer patients. These biopsies are revolutionizing cancer diagnostics and management by offering quicker turnaround times, reduced patient discomfort, and real-time monitoring of tumor progression or therapy response. With rising lung cancer incidence globally and increasing adoption of precision medicine, liquid biopsy is emerging as a powerful tool in oncology diagnostics. This market includes a wide range of products and services, including instruments, reagents, and bioinformatics solutions designed for early detection, genetic profiling, and therapeutic decision-making in both Small Cell Lung Cancer (SCLC) and Non-Small Cell Lung Cancer (NSCLC).

Market Growth Drivers:

The growth of the global lung cancer liquid biopsy market is being significantly driven by the rising global prevalence of lung cancer, coupled with a growing demand for minimally invasive diagnostic procedures. Technological advancements in molecular diagnostics, particularly in next-generation sequencing (NGS) and PCR-based techniques, are making liquid biopsy tests more accurate and accessible. Additionally, increasing focus on personalized medicine is pushing healthcare providers and oncologists to adopt liquid biopsies for real-time tumor profiling and monitoring. Supportive regulatory approvals and increasing healthcare spending, especially in developed nations, are further contributing to market expansion. The growing preference for early and precise cancer detection methods and the potential of liquid biopsies to overcome limitations of traditional tissue biopsies are also propelling market demand.

Market Restraints:

Despite the promising growth trajectory, the lung cancer liquid biopsy market faces several key challenges. High costs associated with advanced liquid biopsy technologies can restrict adoption, particularly in low- and middle-income countries. The sensitivity and specificity of some assays, especially in early-stage cancer detection, remain areas of concern, potentially leading to false positives or negatives. Limited awareness among patients and healthcare providers in certain regions further impedes market penetration. Additionally, stringent regulatory frameworks and reimbursement hurdles can delay product launches and limit accessibility, affecting overall market growth.

Market Opportunities:

The lung cancer liquid biopsy market presents considerable opportunities fueled by the expansion of research into new biomarkers, including extracellular vesicles and circulating tumor cells, which can enhance diagnostic accuracy. The ongoing development of multi-analyte liquid biopsy panels and integration of AI and machine learning in bioinformatics offer pathways to improved diagnostic precision and efficiency. Emerging economies, especially across Asia-Pacific and Latin America, represent untapped potential with growing cancer burden and expanding healthcare infrastructure. Furthermore, collaborations between diagnostic companies and pharmaceutical firms for companion diagnostics in targeted therapies are opening new growth avenues. Continued investment in R&D and clinical trials aimed at validating new biomarker combinations will likely drive innovation and market competitiveness.

Key Questions Answered in the Report:

  • What are the primary factors driving the global lung cancer liquid biopsy market's growth?
  • Which regions and market segments are experiencing the highest demand for lung cancer liquid biopsy diagnostics?
  • How are advancements in genomics and personalized oncology influencing market dynamics?
  • Who are the key players in the lung cancer liquid biopsy market, and what strategies are they adopting to stay competitive?
  • What are the emerging trends and future projections for the global lung cancer liquid biopsy market?

Competitive Intelligence and Business Strategy:

Leading players in the global lung cancer liquid biopsy market, such as Bio-Rad Laboratories, Agilent Technologies, Thermo Fisher Scientific, Illumina, and F. Hoffmann-La Roche, are focusing on developing high-sensitivity diagnostic platforms and expanding their liquid biopsy portfolios. These companies are increasingly investing in strategic collaborations with research institutions and biotech firms to enhance their R&D capabilities. Mergers, acquisitions, and licensing agreements are common strategies aimed at boosting technological integration and expanding global reach. Key players are also emphasizing regulatory approvals and global certifications to gain market trust and improve reimbursement prospects. Efforts to combine multiple biomarkers into single-panel tests and the integration of cloud-based platforms for data interpretation are setting new standards in the field.

Companies Covered in This Report:

  • Bio-Rad Laboratories, Inc.
  • Agilent Technologies, Inc.
  • Oncocyte Corporation
  • NeoGenomics Laboratories
  • Lepu Medical Technology (Beijing) Co., Ltd
  • QIAGEN
  • Thermo Fisher Scientific Inc.
  • Illumina, Inc.
  • F. Hoffmann-La Roche Ltd
  • Sysmex Corporation
  • BioView

Market Segmentation

By Product:

  • Instruments
  • Kits and Reagents
  • Software and Services

By Technology:

  • Multi-gene-parallel Analysis (NGS)
  • Single Gene Analysis (PCR, Microarrays)

By Biomarker:

  • Cell-free DNA (cfDNA)
  • Circulating Tumor DNA (ctDNA)
  • Extracellular Vesicles (EVs)
  • Circulating Tumor Cells (CTC)
  • Others

By Indication:

  • Small Cell Lung Cancer (SCLC)
  • Non-Small Cell Lung Cancer (NSCLC)

By Sample:

  • Blood
  • Cerebrospinal Fluid (CSF)
  • Plasma
  • Serum
  • Others

By End-user:

  • Hospitals
  • Reference Laboratories
  • Academic & Research Centers
  • Others

By Region:

  • North America
  • Europe
  • East Asia
  • South Asia and Oceania
  • Latin America
  • Middle East & Africa

Table of Contents

1. Executive Summary

  • 1.1. Global Lung Cancer Liquid Biopsy Snapshot, 2025-2032
  • 1.2. Market Opportunity Assessment, 2025-2032, US$ Mn
  • 1.3. Key Market Trends
  • 1.4. Future Market Projections
  • 1.5. Premium Market Insights
  • 1.6. Industry Developments and Key Market Events
  • 1.7. PMR Analysis and Recommendations

2. Market Overview

  • 2.1. Market Scope and Definition
  • 2.2. Market Dynamics
    • 2.2.1. Drivers
    • 2.2.2. Restraints
    • 2.2.3. Opportunity
    • 2.2.4. Key Trends
  • 2.3. Macro-Economic Factors
    • 2.3.1. Global Sectorial Outlook
    • 2.3.2. Global GDP Growth Outlook
  • 2.4. COVID-19 Impact Analysis
  • 2.5. Forecast Factors - Relevance and Impact

3. Value Added Insights

  • 3.1. Product Adoption Analysis
  • 3.2. Disease Epidemiology
  • 3.3. Regulatory Landscape
  • 3.4. List of Suppliers
  • 3.5. Porter's Five Forces Analysis
  • 3.6. PESTLE Analysis
  • 3.7. Promotional Strategies, By Key Players

4. Global Lung Cancer Liquid Biopsy Outlook

  • 4.1. Key Highlights
    • 4.1.1. Market Size (US$ Mn) and Y-o-Y Growth
    • 4.1.2. Absolute $ Opportunity
  • 4.2. Market Size (US$ Mn) Analysis and Forecast
    • 4.2.1. Historical Market Size (US$ Mn) Analysis, 2019-2024
    • 4.2.2. Current Market Size (US$ Mn) Analysis and Forecast, 2025-2032
  • 4.3. Global Lung Cancer Liquid Biopsy Outlook: Product
    • 4.3.1. Introduction / Key Findings
    • 4.3.2. Historical Market Size (US$ Mn) Analysis, By Product, 2019-2024
    • 4.3.3. Current Market Size (US$ Mn) Analysis and Forecast, By Product, 2025-2032
      • 4.3.3.1. Instruments
      • 4.3.3.2. Kits and Reagents
      • 4.3.3.3. Software and Services
    • 4.3.4. Market Attractiveness Analysis: Product
  • 4.4. Global Lung Cancer Liquid Biopsy Outlook: Technology
    • 4.4.1. Introduction / Key Findings
    • 4.4.2. Historical Market Size (US$ Mn), By Technology, 2019-2024
    • 4.4.3. Current Market Size (US$ Mn) Analysis and Forecast, By Technology, 2025-2032
      • 4.4.3.1. Multi-gene-parallel Analysis (NGS)
      • 4.4.3.2. Single Gene Analysis (PCR Microarrays)
    • 4.4.4. Market Attractiveness Analysis: Technology
  • 4.5. Global Lung Cancer Liquid Biopsy Outlook: Biomarker
    • 4.5.1. Introduction / Key Findings
    • 4.5.2. Historical Market Size (US$ Mn), By Biomarker, 2019-2024
    • 4.5.3. Current Market Size (US$ Mn) Analysis and Forecast, By Biomarker, 2025-2032
      • 4.5.3.1. Cell-free DNA (cfDNA)
      • 4.5.3.2. Circulating tumor DNA (ctDNA)
      • 4.5.3.3. Extracellular Vesicles (EVs)
      • 4.5.3.4. Circulating Tumor Cells (CTC)
      • 4.5.3.5. Others
    • 4.5.4. Market Attractiveness Analysis: Biomarker
  • 4.6. Global Lung Cancer Liquid Biopsy Outlook: Indication
    • 4.6.1. Introduction / Key Findings
    • 4.6.2. Historical Market Size (US$ Mn), By Indication, 2019-2024
    • 4.6.3. Current Market Size (US$ Mn) Analysis and Forecast, By Indication, 2025-2032
      • 4.6.3.1. Small Cell Lung Cancer (SCLC)
      • 4.6.3.2. Non-Small Cell Lung Cancer (NSCLC)
    • 4.6.4. Market Attractiveness Analysis: Indication
  • 4.7. Global Lung Cancer Liquid Biopsy Outlook: Sample
    • 4.7.1. Introduction / Key Findings
    • 4.7.2. Historical Market Size (US$ Mn), By Sample, 2019-2024
    • 4.7.3. Current Market Size (US$ Mn) Analysis and Forecast, By Sample, 2025-2032
      • 4.7.3.1. Blood
      • 4.7.3.2. Cerebrospinal Fluid (CSF)
      • 4.7.3.3. Plasma
      • 4.7.3.4. Serum
      • 4.7.3.5. Others
    • 4.7.4. Market Attractiveness Analysis: Sample
  • 4.8. Global Lung Cancer Liquid Biopsy Outlook: End User
    • 4.8.1. Introduction / Key Findings
    • 4.8.2. Historical Market Size (US$ Mn), By End User, 2019-2024
    • 4.8.3. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2025-2032
      • 4.8.3.1. Hospitals
      • 4.8.3.2. Reference Laboratories
      • 4.8.3.3. Academic & Research Institutes
      • 4.8.3.4. Others
    • 4.8.4. Market Attractiveness Analysis: End User

5. Global Lung Cancer Liquid Biopsy Outlook: Region

  • 5.1. Key Highlights
  • 5.2. Historical Market Size (US$ Mn) Analysis, By Region, 2019-2024
  • 5.3. Current Market Size (US$ Mn) Analysis and Forecast, By Region, 2025-2032
    • 5.3.1. North America
    • 5.3.2. Europe
    • 5.3.3. East Asia
    • 5.3.4. South Asia and Oceania
    • 5.3.5. Latin America
    • 5.3.6. Middle East & Africa
  • 5.4. Market Attractiveness Analysis: Region

6. North America Lung Cancer Liquid Biopsy Outlook

  • 6.1. Key Highlights
  • 6.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
    • 6.2.1. By Country
    • 6.2.2. By Product
    • 6.2.3. By Technology
    • 6.2.4. By Biomarker
    • 6.2.5. By Indication
    • 6.2.6. By Sample
    • 6.2.7. By End User
  • 6.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
    • 6.3.1. U.S.
    • 6.3.2. Canada
  • 6.4. Current Market Size (US$ Mn) Analysis and Forecast, By Product, 2025-2032
    • 6.4.1. Instruments
    • 6.4.2. Kits and Reagents
    • 6.4.3. Software and Services
  • 6.5. Current Market Size (US$ Mn) Analysis and Forecast, By Technology, 2025-2032
    • 6.5.1. Multi-gene-parallel Analysis (NGS)
    • 6.5.2. Single Gene Analysis (PCR Microarrays)
  • 6.6. Current Market Size (US$ Mn) Analysis and Forecast, By Biomarker, 2025-2032
    • 6.6.1. Cell-free DNA (cfDNA)
    • 6.6.2. Circulating tumor DNA (ctDNA)
    • 6.6.3. Extracellular Vesicles (EVs)
    • 6.6.4. Circulating Tumor Cells (CTC)
    • 6.6.5. Others
  • 6.7. Current Market Size (US$ Mn) Analysis and Forecast, By Indication, 2025-2032
    • 6.7.1. Small Cell Lung Cancer (SCLC)
    • 6.7.2. Non-Small Cell Lung Cancer (NSCLC)
  • 6.8. Current Market Size (US$ Mn) Analysis and Forecast, By Sample, 2025-2032
    • 6.8.1. Blood
    • 6.8.2. Cerebrospinal Fluid (CSF)
    • 6.8.3. Plasma
    • 6.8.4. Serum
    • 6.8.5. Others
  • 6.9. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2025-2032
    • 6.9.1. Hospitals
    • 6.9.2. Reference Laboratories
    • 6.9.3. Academic & Research Institutes
    • 6.9.4. Others
  • 6.10. Market Attractiveness Analysis

7. Europe Lung Cancer Liquid Biopsy Outlook

  • 7.1. Key Highlights
  • 7.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
    • 7.2.1. By Country
    • 7.2.2. By Product
    • 7.2.3. By Technology
    • 7.2.4. By Biomarker
    • 7.2.5. By Indication
    • 7.2.6. By Sample
    • 7.2.7. By End User
  • 7.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
    • 7.3.1. Germany
    • 7.3.2. France
    • 7.3.3. U.K.
    • 7.3.4. Italy
    • 7.3.5. Spain
    • 7.3.6. Russia
    • 7.3.7. Turkey
    • 7.3.8. Rest of Europe
  • 7.4. Current Market Size (US$ Mn) Analysis and Forecast, By Product, 2025-2032
    • 7.4.1. Instruments
    • 7.4.2. Kits and Reagents
    • 7.4.3. Software and Services
  • 7.5. Current Market Size (US$ Mn) Analysis and Forecast, By Technology, 2025-2032
    • 7.5.1. Multi-gene-parallel Analysis (NGS)
    • 7.5.2. Single Gene Analysis (PCR Microarrays)
  • 7.6. Current Market Size (US$ Mn) Analysis and Forecast, By Biomarker, 2025-2032
    • 7.6.1. Cell-free DNA (cfDNA)
    • 7.6.2. Circulating tumor DNA (ctDNA)
    • 7.6.3. Extracellular Vesicles (EVs)
    • 7.6.4. Circulating Tumor Cells (CTC)
    • 7.6.5. Others
  • 7.7. Current Market Size (US$ Mn) Analysis and Forecast, By Indication, 2025-2032
    • 7.7.1. Small Cell Lung Cancer (SCLC)
    • 7.7.2. Non-Small Cell Lung Cancer (NSCLC)
  • 7.8. Current Market Size (US$ Mn) Analysis and Forecast, By Sample, 2025-2032
    • 7.8.1. Blood
    • 7.8.2. Cerebrospinal Fluid (CSF)
    • 7.8.3. Plasma
    • 7.8.4. Serum
    • 7.8.5. Others
  • 7.9. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2025-2032
    • 7.9.1. Hospitals
    • 7.9.2. Reference Laboratories
    • 7.9.3. Academic & Research Institutes
    • 7.9.4. Others
  • 7.10. Market Attractiveness Analysis

8. East Asia Lung Cancer Liquid Biopsy Outlook

  • 8.1. Key Highlights
  • 8.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
    • 8.2.1. By Country
    • 8.2.2. By Product
    • 8.2.3. By Technology
    • 8.2.4. By Biomarker
    • 8.2.5. By Indication
    • 8.2.6. By Sample
    • 8.2.7. By End User
  • 8.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
    • 8.3.1. China
    • 8.3.2. Japan
    • 8.3.3. South Korea
  • 8.4. Current Market Size (US$ Mn) Analysis and Forecast, By Product, 2025-2032
    • 8.4.1. Instruments
    • 8.4.2. Kits and Reagents
    • 8.4.3. Software and Services
  • 8.5. Current Market Size (US$ Mn) Analysis and Forecast, By Technology, 2025-2032
    • 8.5.1. Multi-gene-parallel Analysis (NGS)
    • 8.5.2. Single Gene Analysis (PCR Microarrays)
  • 8.6. Current Market Size (US$ Mn) Analysis and Forecast, By Biomarker, 2025-2032
    • 8.6.1. Cell-free DNA (cfDNA)
    • 8.6.2. Circulating tumor DNA (ctDNA)
    • 8.6.3. Extracellular Vesicles (EVs)
    • 8.6.4. Circulating Tumor Cells (CTC)
    • 8.6.5. Others
  • 8.7. Current Market Size (US$ Mn) Analysis and Forecast, By Indication, 2025-2032
    • 8.7.1. Small Cell Lung Cancer (SCLC)
    • 8.7.2. Non-Small Cell Lung Cancer (NSCLC)
  • 8.8. Current Market Size (US$ Mn) Analysis and Forecast, By Sample, 2025-2032
    • 8.8.1. Blood
    • 8.8.2. Cerebrospinal Fluid (CSF)
    • 8.8.3. Plasma
    • 8.8.4. Serum
    • 8.8.5. Others
  • 8.9. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2025-2032
    • 8.9.1. Hospitals
    • 8.9.2. Reference Laboratories
    • 8.9.3. Academic & Research Institutes
    • 8.9.4. Others
  • 8.10. Market Attractiveness Analysis

9. South Asia & Oceania Lung Cancer Liquid Biopsy Outlook

  • 9.1. Key Highlights
  • 9.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
    • 9.2.1. By Country
    • 9.2.2. By Product
    • 9.2.3. By Technology
    • 9.2.4. By Biomarker
    • 9.2.5. By Indication
    • 9.2.6. By Sample
    • 9.2.7. By End User
  • 9.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
    • 9.3.1. India
    • 9.3.2. Southeast Asia
    • 9.3.3. ANZ
    • 9.3.4. Rest of South Asia & Oceania
  • 9.4. Current Market Size (US$ Mn) Analysis and Forecast, By Product, 2025-2032
    • 9.4.1. Instruments
    • 9.4.2. Kits and Reagents
    • 9.4.3. Software and Services
  • 9.5. Current Market Size (US$ Mn) Analysis and Forecast, By Technology, 2025-2032
    • 9.5.1. Multi-gene-parallel Analysis (NGS)
    • 9.5.2. Single Gene Analysis (PCR Microarrays)
  • 9.6. Current Market Size (US$ Mn) Analysis and Forecast, By Biomarker, 2025-2032
    • 9.6.1. Cell-free DNA (cfDNA)
    • 9.6.2. Circulating tumor DNA (ctDNA)
    • 9.6.3. Extracellular Vesicles (EVs)
    • 9.6.4. Circulating Tumor Cells (CTC)
    • 9.6.5. Others
  • 9.7. Current Market Size (US$ Mn) Analysis and Forecast, By Indication, 2025-2032
    • 9.7.1. Small Cell Lung Cancer (SCLC)
    • 9.7.2. Non-Small Cell Lung Cancer (NSCLC)
  • 9.8. Current Market Size (US$ Mn) Analysis and Forecast, By Sample, 2025-2032
    • 9.8.1. Blood
    • 9.8.2. Cerebrospinal Fluid (CSF)
    • 9.8.3. Plasma
    • 9.8.4. Serum
    • 9.8.5. Others
  • 9.9. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2025-2032
    • 9.9.1. Hospitals
    • 9.9.2. Reference Laboratories
    • 9.9.3. Academic & Research Institutes
    • 9.9.4. Others
  • 9.10. Market Attractiveness Analysis

10. Latin America Lung Cancer Liquid Biopsy Outlook

  • 10.1. Key Highlights
  • 10.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
    • 10.2.1. By Country
    • 10.2.2. By Product
    • 10.2.3. By Technology
    • 10.2.4. By Biomarker
    • 10.2.5. By Indication
    • 10.2.6. By Sample
    • 10.2.7. By End User
  • 10.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
    • 10.3.1. Brazil
    • 10.3.2. Mexico
    • 10.3.3. Rest of Latin America
  • 10.4. Current Market Size (US$ Mn) Analysis and Forecast, By Product, 2025-2032
    • 10.4.1. Instruments
    • 10.4.2. Kits and Reagents
    • 10.4.3. Software and Services
  • 10.5. Current Market Size (US$ Mn) Analysis and Forecast, By Technology, 2025-2032
    • 10.5.1. Multi-gene-parallel Analysis (NGS)
    • 10.5.2. Single Gene Analysis (PCR Microarrays)
  • 10.6. Current Market Size (US$ Mn) Analysis and Forecast, By Biomarker, 2025-2032
    • 10.6.1. Cell-free DNA (cfDNA)
    • 10.6.2. Circulating tumor DNA (ctDNA)
    • 10.6.3. Extracellular Vesicles (EVs)
    • 10.6.4. Circulating Tumor Cells (CTC)
    • 10.6.5. Others
  • 10.7. Current Market Size (US$ Mn) Analysis and Forecast, By Indication, 2025-2032
    • 10.7.1. Small Cell Lung Cancer (SCLC)
    • 10.7.2. Non-Small Cell Lung Cancer (NSCLC)
  • 10.8. Current Market Size (US$ Mn) Analysis and Forecast, By Sample, 2025-2032
    • 10.8.1. Blood
    • 10.8.2. Cerebrospinal Fluid (CSF)
    • 10.8.3. Plasma
    • 10.8.4. Serum
    • 10.8.5. Others
  • 10.9. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2025-2032
    • 10.9.1. Hospitals
    • 10.9.2. Reference Laboratories
    • 10.9.3. Academic & Research Institutes
    • 10.9.4. Others
  • 10.10. Market Attractiveness Analysis

11. Middle East & Africa Lung Cancer Liquid Biopsy Outlook

  • 11.1. Key Highlights
  • 11.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
    • 11.2.1. By Country
    • 11.2.2. By Product
    • 11.2.3. By Technology
    • 11.2.4. By Biomarker
    • 11.2.5. By Indication
    • 11.2.6. By Sample
    • 11.2.7. By End User
  • 11.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
    • 11.3.1. GCC Countries
    • 11.3.2. Egypt
    • 11.3.3. South Africa
    • 11.3.4. Northern Africa
    • 11.3.5. Rest of Middle East & Africa
  • 11.4. Current Market Size (US$ Mn) Analysis and Forecast, By Product, 2025-2032
    • 11.4.1. Instruments
    • 11.4.2. Kits and Reagents
    • 11.4.3. Software and Services
  • 11.5. Current Market Size (US$ Mn) Analysis and Forecast, By Technology, 2025-2032
    • 11.5.1. Multi-gene-parallel Analysis (NGS)
    • 11.5.2. Single Gene Analysis (PCR Microarrays)
  • 11.6. Current Market Size (US$ Mn) Analysis and Forecast, By Biomarker, 2025-2032
    • 11.6.1. Cell-free DNA (cfDNA)
    • 11.6.2. Circulating tumor DNA (ctDNA)
    • 11.6.3. Extracellular Vesicles (EVs)
    • 11.6.4. Circulating Tumor Cells (CTC)
    • 11.6.5. Others
  • 11.7. Current Market Size (US$ Mn) Analysis and Forecast, By Indication, 2025-2032
    • 11.7.1. Small Cell Lung Cancer (SCLC)
    • 11.7.2. Non-Small Cell Lung Cancer (NSCLC)
  • 11.8. Current Market Size (US$ Mn) Analysis and Forecast, By Sample, 2025-2032
    • 11.8.1. Blood
    • 11.8.2. Cerebrospinal Fluid (CSF)
    • 11.8.3. Plasma
    • 11.8.4. Serum
    • 11.8.5. Others
  • 11.9. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2025-2032
    • 11.9.1. Hospitals
    • 11.9.2. Reference Laboratories
    • 11.9.3. Academic & Research Institutes
    • 11.9.4. Others
  • 11.10. Market Attractiveness Analysis

12. Competition Landscape

  • 12.1. Market Share Analysis, 2025
  • 12.2. Market Structure
    • 12.2.1. Competition Intensity Mapping By Market
    • 12.2.2. Competition Dashboard
  • 12.3. Company Profiles (Details - Overview, Financials, Strategy, Recent Developments)
    • 12.3.1. Bio-Rad Laboratories, Inc.
      • 12.3.1.1. Overview
      • 12.3.1.2. Segments and Products
      • 12.3.1.3. Key Financials
      • 12.3.1.4. Market Developments
      • 12.3.1.5. Market Strategy
    • 12.3.2. Agilent Technologies, Inc.
    • 12.3.3. Oncocyte Corporation
    • 12.3.4. NeoGenomics Laboratories
    • 12.3.5. Lepu Medical Technology(Beijing)Co.,Ltd
    • 12.3.6. QIAGEN
    • 12.3.7. Thermo Fisher Scientific Inc.
    • 12.3.8. Illumina, Inc.
    • 12.3.9. F. Hoffmann-La Roche Ltd
    • 12.3.10. Sysmex Corporation
    • 12.3.11. BioView
    • 12.3.12. Guardant Health, Inc
    • 12.3.13. SOPHiA GENETICS
    • 12.3.14. BioMark Diagnostics
    • 12.3.15. DELFI Diagnostics, Inc.
    • 12.3.16. Freenome Holdings, Inc.
    • 12.3.17. Foresight Diagnostics, Inc.
    • 12.3.18. Foundation Medicine, Inc.
    • 12.3.19. Pillar Biosciences, Inc.
    • 12.3.20. Caris Life Sciences

13. Appendix

  • 13.1. Research Methodology
  • 13.2. Research Assumptions
  • 13.3. Acronyms and Abbreviations